Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Artrya Limited ( (AU:AYA) ) has shared an update.
Artrya Limited has secured a three-year commercial agreement with Northeast Georgia Health System (NGHS), marking its second U.S. customer for the Salix® platform. The agreement, valued at a minimum of US$0.3 million, includes a SaaS license for the Salix® Coronary Anatomy platform and fee-per-scan revenue from the Salix® Coronary Plaque module, with potential expansion upon FDA clearance of the Salix® Coronary Flow module. This partnership is a significant step in Artrya’s U.S. expansion strategy, integrating its AI-powered platform into NGHS’s clinical workflow to enhance cardiovascular care and diagnostic precision. The rollout will be supported by Artrya’s Customer Success team in Atlanta, ensuring seamless integration and support for NGHS’s network of hospitals and the Georgia Heart Institute.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya is focused on advancing cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.
Average Trading Volume: 926,098
Technical Sentiment Signal: Hold
Current Market Cap: A$545.4M
See more data about AYA stock on TipRanks’ Stock Analysis page.